- Home
- Automated
- NDF A-Z listing
- Glycopyrronium
G
Glycopyrronium
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Glycopyrronium
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
02/07/2018 LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
The Ministry of Health’s Drug Advisory Committee has recommended:
Umeclidinium 62.5mcg inhalation powder for the:
Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have breathlessness.
Umeclidinium/vilanterol 62.5/25mcg inhalation powder for the:
Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have frequent exacerbations (at least 2 per year or at least 1 leading to hospitalisation per year) and/or persistent breathlessness despite treatment with LAMA monotherapy.
Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group D) with persistent symptoms and frequent exacerbations.
Subsidy status
[R] Umeclidinium 62.5mcg inhalation powder and umeclidinium/vilanterol 62.5/25mcg inhalation powder are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
[NR] SDL subsidies do not apply to the following:
Other LAMAs (glycopyrronium, tiotropium or aclidinium)
Other LAMA/LABAs (indacaterol/glycopyrronium, tiotropium/olodaterol or aclidinium/formoterol)
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |